Ambalal Sarabhai Enterprises Ltd

Ambalal Sarabhai Enterprises Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 March 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Ambalal Sarabhai Enterprises Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Ambalal Sarabhai Enterprises Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 19 Feb 2026, reflecting deteriorating technical indicators and persistent fundamental weaknesses. Despite some positive quarterly financial results, the stock’s overall outlook has worsened due to bearish technical trends, subpar valuation metrics, and disappointing long-term financial performance.

Ambalal Sarabhai Enterprises Ltd has seen its investment rating upgraded from Strong Sell to Sell, reflecting notable improvements in its financial performance and technical outlook. Despite lingering challenges in long-term fundamentals, the company’s recent quarterly results and market behaviour have prompted a reassessment of its prospects, signalling cautious optimism among investors.

Ambalal Sarabhai Enterprises Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹201.00 crores, reported consolidated net profit of ₹3.64 crores in Q3 FY26, marking a dramatic turnaround from the ₹0.56 crore loss in Q2 FY26. However, beneath the headline recovery lies a troubling narrative of margin compression, heavy reliance on non-operating income, and persistent operational weakness that has pushed the stock down 48.30% over the past year.

Ambalal Sarabhai Enterprises Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 02 June 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 08 February 2026, providing investors with the most recent and relevant data to assess the company’s outlook.

Ambalal Sarabhai Enterprises Ltd, a player in the Pharmaceuticals & Biotechnology sector, recorded a new 52-week low of Rs.23.12 today, marking a significant decline in its stock price amid broader market movements.

Ambalal Sarabhai Enterprises Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 02 June 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 28 January 2026, providing investors with the latest insights into its performance and prospects.

Ambalal Sarabhai Enterprises Ltd’s shares declined to a fresh 52-week low of Rs.24 today, marking a significant downturn in the stock’s performance amid ongoing pressures in the Pharmaceuticals & Biotechnology sector. The stock’s fall comes despite a modest outperformance relative to its sector peers during the trading session.

Ambalal Sarabhai Enterprises Ltd, a player in the Pharmaceuticals & Biotechnology sector, recorded a new 52-week low of Rs.25.8 today, marking a significant decline in its stock price amid broader market fluctuations and company-specific performance concerns.

Ambalal Sarabhai Enterprises Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 02 June 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 05 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Ambalal Sarabhai Enterprises Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 02 June 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 December 2025, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Ambalal Sarabhai Enterprises, a player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of Rs.26.51, marking a significant decline amid broader market fluctuations. The stock's recent performance reflects ongoing pressures within the company’s financial metrics and market positioning.

Ambalal Sarabhai Enterprises has reached a new 52-week low of Rs.26.51, marking a significant decline in its stock price amid broader market fluctuations and company-specific performance factors.

Ambalal Sarabhai Enterprises has reached a new 52-week low of Rs.26.51, marking a significant decline in its stock price amid broader market fluctuations and sector-specific pressures.